Healthcare | January 14, 2026
Firstsource acquires TeleMedik
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
The acquisition combines Firstsource’s market-leading AI and automation capabilities with TeleMedik’s operational footprint in Puerto Rico
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
